
Wooin Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1343801/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Drug and Bile Acid Transporters in Rosuvastatin Hepatic Uptake: Function, Expression, and Pharmacogenetics. Gastroenterology, 2006, 130, 1793-1806.	1.3	542
2	The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nature Medicine, 2003, 9, 220-224.	30.7	418
3	Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans. Clinical Pharmacology and Therapeutics, 2007, 81, 362-370.	4.7	374
4	Polymorphisms in Human Organic Anion-transporting Polypeptide 1A2 (OATP1A2). Journal of Biological Chemistry, 2005, 280, 9610-9617.	3.4	316
5	Transporters and Renal Drug Elimination. Annual Review of Pharmacology and Toxicology, 2004, 44, 137-166.	9.4	210
6	Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenetics and Genomics, 2007, 17, 647-656.	1.5	172
7	Ethnicity-dependent Polymorphism in Na+-taurocholate Cotransporting Polypeptide (SLC10A1) Reveals a Domain Critical for Bile Acid Substrate Recognition. Journal of Biological Chemistry, 2004, 279, 7213-7222.	3.4	167
8	Overexpression of OATP1B3 Confers Apoptotic Resistance in Colon Cancer. Cancer Research, 2008, 68, 10315-10323.	0.9	122
9	Cancer Pharmacogenomics: Powerful Tools in Cancer Chemotherapy and Drug Development. Oncologist, 2005, 10, 104-111.	3.7	116
10	Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumors. Biomaterials, 2018, 180, 206-224.	11.4	110
11	HEPATIC UPTAKE OF THE NOVEL ANTIFUNGAL AGENT CASPOFUNGIN. Drug Metabolism and Disposition, 2005, 33, 676-682.	3.3	105
12	Next-generation proteasome inhibitors for cancer therapy. Translational Research, 2018, 198, 1-16.	5.0	99
13	Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy. AAPS Journal, 2015, 17, 535-545.	4.4	91
14	Inhibitors of the Immunoproteasome: Current Status and Future Directions. Current Pharmaceutical Design, 2013, 19, 4140-4151.	1.9	85
15	Novel Mechanistic Insights into Ectodomain Shedding of EGFR Ligands Amphiregulin and TGF-α: Impact on Gastrointestinal Cancers Driven by Secondary Bile Acids. Cancer Research, 2014, 74, 2062-2072.	0.9	80
16	Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncology, 2016, 58, 41-48.	1.5	78
17	A Cancer-Specific Variant of the <i>SLCO1B3</i> Gene Encodes a Novel Human Organic Anion Transporting Polypeptide 1B3 (OATP1B3) Localized Mainly in the Cytoplasm of Colon and Pancreatic Cancer Cells. Molecular Pharmaceutics, 2013, 10, 406-416.	4.6	75
18	A Common Polymorphism in the Bile Acid Receptor Farnesoid X Receptor Is Associated with Decreased Hepatic Target Gene Expression. Molecular Endocrinology, 2007, 21, 1769-1780.	3.7	61

#	Article	IF	CITATIONS
19	Phase 0/microdosing approaches: time for mainstream application in drug development?. Nature Reviews Drug Discovery, 2020, 19, 801-818.	46.4	55
20	A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2010, 65, 833-838.	2.3	52
21	Sustained Delivery of Carfilzomib by Tannic Acid-Based Nanocapsules Helps Develop Antitumor Immunity. Nano Letters, 2019, 19, 8333-8341.	9.1	51
22	Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors. Clinical Cancer Research, 2011, 17, 3794-3802.	7.0	49
23	A Comparative In Vivo Study of Albuminâ€Coated Paclitaxel Nanocrystals and Abraxane. Small, 2018, 14, e1703670.	10.0	47
24	Proteasome Inhibitors with Pyrazole Scaffolds from Structure-Based Virtual Screening. Journal of Medicinal Chemistry, 2015, 58, 2036-2041.	6.4	45
25	Development of Peptide-Based Reversing Agents for P-Glycoprotein-Mediated Resistance to Carfilzomib. Molecular Pharmaceutics, 2012, 9, 2197-2205.	4.6	41
26	Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2012, 70, 699-705.	2.3	41
27	Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drugâ€Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 186-196.	2.5	41
28	Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation. Journal of Controlled Release, 2019, 302, 148-159.	9.9	41
29	Organic anion transporting polypeptide 1B3 (OATP1B3) is overexpressed in colorectal tumors and is a predictor of clinical outcome. Clinical and Experimental Gastroenterology, 2008, 1, 1.	2.3	36
30	Polymer Micelle Formulations of Proteasome Inhibitor Carfilzomib for Improved Metabolic Stability and Anticancer Efficacy in Human Multiple Myeloma and Lung Cancer Cell Lines. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 168-173.	2.5	35
31	Lack of critical involvement of endothelial nitric oxide synthase in vascular nitrate tolerance in mice. British Journal of Pharmacology, 2002, 135, 299-302.	5.4	32
32	Role of hypoxia inducible factor-1α in the regulation of the cancer-specific variant of organic anion transporting polypeptide 1B3 (OATP1B3), in colon and pancreatic cancer. Biochemical Pharmacology, 2013, 86, 816-823.	4.4	32
33	Emerging immunotherapy for the treatment of esophageal cancer. Expert Opinion on Investigational Drugs, 2016, 25, 667-677.	4.1	32
34	Statistical methods for assays with limits of detection: Serum bile acid as a differentiator between patients with normal colons, adenomas, and colorectal cancer. Journal of Carcinogenesis, 2011, 10, 12.	2.5	29
35	Expanded Physiologicallyâ€Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 845-857.	2.5	28
36	Post-translational regulation of the major drug transporters in the families of organic anion transporters and organic anion–transporting polypeptides. Journal of Biological Chemistry, 2020, 295, 17349-17364.	3.4	28

#	Article	IF	CITATIONS
37	Kinetics of the Absorption, Distribution, Metabolism, and Excretion of Lobeglitazone, a Novel Activator of Peroxisome Proliferator-Activated Receptor Gamma in Rats. Journal of Pharmaceutical Sciences, 2015, 104, 3049-3059.	3.3	27
38	Physiologicallyâ€Based Pharmacokinetic Modeling Analysis for Quantitative Prediction of Renal Transporter–Mediated Interactions Between Metformin and Cimetidine. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 396-406.	2.5	26
39	Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. , 1998, 19, 357-364.		25
40	Mechanism-based partial inactivation of glutathione S-transferases by nitroglycerin: tyrosine nitration vs sulfhydryl oxidation. Nitric Oxide - Biology and Chemistry, 2003, 8, 103-110.	2.7	25
41	Revisiting the role of the immunoproteasome in the activation of the canonical NF-κB pathway. Molecular BioSystems, 2012, 8, 2295.	2.9	25
42	Enhancing Docetaxel Delivery to Multidrug-Resistant Cancer Cells with Albumin-Coated Nanocrystals. Molecular Pharmaceutics, 2018, 15, 871-881.	4.6	25
43	Quinic Acid onjugated Nanoparticles Enhance Drug Delivery to Solid Tumors via Interactions with Endothelial Selectins. Small, 2018, 14, e1803601.	10.0	25
44	Essential Role of DNA Methyltransferase 1–mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors. Clinical Cancer Research, 2017, 23, 1299-1311.	7.0	24
45	Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancer. Oncogene, 2020, 39, 4567-4580.	5.9	22
46	Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx. Molecular Cancer Research, 2017, 15, 1096-1105.	3.4	20
47	Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib. Journal of Medicinal Chemistry, 2019, 62, 4444-4455.	6.4	20
48	The Immunoproteasome: An Emerging Therapeutic Target. Current Topics in Medicinal Chemistry, 2011, 11, 2923-2930.	2.1	19
49	Novel targets in esophageal and gastric cancer: beyond antiangiogenesis. Expert Opinion on Investigational Drugs, 2009, 18, 1351-1364.	4.1	18
50	Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice. PLoS ONE, 2017, 12, e0173247.	2.5	18
51	Physiologically Based Pharmacokinetic Modeling of Bosentan Identifies the Saturable Hepatic Uptake As a Major Contributor to Its Nonlinear Pharmacokinetics. Drug Metabolism and Disposition, 2018, 46, 740-748.	3.3	18
52	The N-terminal region of organic anion transporting polypeptide 1B3 (OATP1B3) plays an essential role in regulating its plasma membrane trafficking. Biochemical Pharmacology, 2017, 131, 98-105.	4.4	17
53	Strategies to improve the prediction accuracy of hepatic intrinsic clearance of three antidiabetic drugs: Application of the extended clearance concept and consideration of the effect of albumin on CYP2C metabolism and OATP1B-mediated hepatic uptake. European Journal of Pharmaceutical Sciences, 2018. 125. 181-192.	4.0	17
54	Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors. European Journal of Clinical Pharmacology, 2013, 69, 2073-2081.	1.9	16

#	Article	IF	CITATIONS
55	Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors. International Journal of Nanomedicine, 2015, 10, 1201.	6.7	16
56	The Immunoproteasome as a Therapeutic Target for Hematological Malignancies. Current Cancer Drug Targets, 2014, 14, 537-548.	1.6	16
57	Activityâ€Based Nearâ€Infrared Fluorescent Probe for LMP7: A Chemical Proteomics Tool for the Immunoproteasome in Living Cells. ChemBioChem, 2012, 13, 1899-1903.	2.6	15
58	Experimental and Modeling Evidence Supporting the <i>Trans</i> -Inhibition Mechanism for Preincubation Time-Dependent, Long-Lasting Inhibition of Organic Anion Transporting Polypeptide 1B1 by Cyclosporine A. Drug Metabolism and Disposition, 2022, 50, 541-551.	3.3	12
59	PSMB9 Codon 60 Polymorphisms Have No Impact on the Activity of the Immunoproteasome Catalytic Subunit B1i Expressed in Multiple Types of Solid Cancer. PLoS ONE, 2013, 8, e73732.	2.5	11
60	Comparative and quantitative assessment on statin efficacy and safety: insights into inter-statin and inter-individual variability via dose- and exposure-response relationships. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 897-911.	3.3	11
61	H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth. Scientific Reports, 2019, 9, 4089.	3.3	11
62	A FRET-based approach for identification of proteasome catalytic subunit composition. Molecular BioSystems, 2014, 10, 196-200.	2.9	10
63	Tethered polymer nanoassemblies for sustained carfilzomib release and prolonged suppression of proteasome activity. Therapeutic Delivery, 2016, 7, 665-681.	2.2	10
64	Consideration of albumin-mediated hepatic uptake for highly protein-bound anionic drugs: Bridging the gap of hepatic uptake clearance between in vitro and in vivo. , 2022, 229, 107938.		10
65	Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotypeâ€Guided Dosing of Tamoxifen. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 474-482.	2.5	10
66	Differential interactions of nitric oxide donors with rat oxyhemoglobin. Biochemical Pharmacology, 1999, 58, 671-674.	4.4	9
67	eNOS-dependent vascular interaction between nitric oxide and calcitonin gene-related peptide in mice: gender selectivity and effects on blood aggregation. Regulatory Peptides, 2003, 110, 115-122.	1.9	9
68	Determination of chemically reduced pyrrolobenzodiazepine SJGâ€136 in human plasma by HPLCâ€MS/MS: application to an anticancer phase I dose escalation study. Journal of Mass Spectrometry, 2008, 43, 42-52.	1.6	9
69	Highâ€Resolution Snapshots of Proteasome Inhibitors in Action Revise Inhibition Paradigms and Inspire Nextâ€Generation Inhibitor Design. ChemBioChem, 2016, 17, 2115-2117.	2.6	9
70	Inhibition of Organic Anion Transporting Polypeptide 1B1 and 1B3 by Betulinic Acid: Effects of Preincubation and Albumin in the Media. Journal of Pharmaceutical Sciences, 2018, 107, 1713-1723.	3.3	9
71	Evaluation of Hepatic Uptake of OATP1B Substrates by Short Term-Cultured Plated Human Hepatocytes: Comparison With Isolated Suspended Hepatocytes. Journal of Pharmaceutical Sciences, 2021, 110, 376-387.	3.3	8
72	Effect of Enhancers on <i>in vitro</i> and <i>in vivo</i> Skin Permeation and Deposition of S-Methyl- _L -Methionine. Biomolecules and Therapeutics, 2017, 25, 434-440.	2.4	8

#	Article	IF	CITATIONS
73	Transient, Tunable Expression of NTCP and BSEP in MDCKII Cells for Kinetic Delineation of the Rate-Determining Process and Inhibitory Effects of Rifampicin in Hepatobiliary Transport of Taurocholate. Journal of Pharmaceutical Sciences, 2021, 110, 365-375.	3.3	7
74	Revisiting Nonlinear Bosentan Pharmacokinetics by Physiologically Based Pharmacokinetic Modeling: Target Binding, Albeit Not a Major Contributor to Nonlinearity, Can Offer Prediction of Target Occupancy. Drug Metabolism and Disposition, 2021, 49, 298-304.	3.3	7
75	Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease. Journal of Medicinal Chemistry, 2021, 64, 10934-10950.	6.4	7
76	Thymidylate Synthase Genotype-Directed Chemotherapy for Patients with Gastric and Gastroesophageal Junction Cancers. PLoS ONE, 2014, 9, e107424.	2.5	6
77	Alternative Splicing: Expanding Diversity in Major ABC and SLC Drug Transporters. AAPS Journal, 2017, 19, 1643-1655.	4.4	6
78	Quantitative determination of carfilzomib in mouse plasma by liquid chromatography–tandem mass spectrometry and its application to a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2017, 146, 341-346.	2.8	6
79	Runx3 inhibits endothelial progenitor cell differentiation and function via suppression of HIF-1α activity. International Journal of Oncology, 2019, 54, 1327-1336.	3.3	6
80	Improved Prediction of the Drug-Drug Interactions of Pemafibrate Caused by Cyclosporine A and Rifampicin via PBPK Modeling: Consideration of the Albumin-Mediated Hepatic Uptake of Pemafibrate and Inhibition Constants With Preincubation Against OATP1B. Journal of Pharmaceutical Sciences, 2021, 110, 517-528.	3.3	6
81	Metabolic changes of acetaminophen after intravenous administration to rats pretreated with 2-(allylthio)pyrazine. , 1998, 19, 273-277.		5
82	The identification of lobeglitazone metabolites in rat liver microsomes and the kinetics of the in vivo formation of the major metabolite M1 in rats. Journal of Pharmaceutical and Biomedical Analysis, 2015, 115, 375-382.	2.8	5
83	Targeted Degradation of Proteins by PROTACs. Current Protocols in Chemical Biology, 2010, 2, 71-87.	1.7	4
84	A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies. Cancer Chemotherapy and Pharmacology, 2014, 74, 419-426.	2.3	4
85	Elucidating the Catalytic Subunit Composition of Distinct Proteasome Subtypes: A Crosslinking Approach Employing Bifunctional Activityâ€Based Probes. ChemBioChem, 2015, 16, 284-292.	2.6	4
86	Suppression of Canine ATP Binding Cassette ABCB1 in Madin-Darby Canine Kidney Type II Cells Unmasks Human ABCG2-Mediated Efflux of Olaparib. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 79-87.	2.5	4
87	Cell-to-Medium Concentration Ratio Overshoot in the Uptake of Statins by Human Hepatocytes in Suspension, but Not in Monolayer: Kinetic Analysis Suggesting a Partial Loss of Functional OATP1Bs. AAPS Journal, 2020, 22, 133.	4.4	4
88	Feasibility of the functional expression of the human organic anion transporting polypeptide 1B1 (OATP1B1) and its genetic variant 521T/C in the mouse liver. European Journal of Pharmaceutical Sciences, 2017, 96, 28-36.	4.0	3
89	Carfilzomib Delivery by Quinic Acid-Conjugated Nanoparticles: Discrepancy Between Tumoral Drug Accumulation and Anticancer Efficacy in a Murine 4T1 Orthotopic Breast Cancer Model. Journal of Pharmaceutical Sciences, 2020, 109, 1615-1622.	3.3	3
90	Pharmacokinetic aspects of the clinically used proteasome inhibitor drugs and efforts toward nanoparticulate delivery systems. Journal of Pharmaceutical Investigation, 2021, 51, 483.	5.3	3

#	Article	IF	CITATIONS
91	COMPARISON OF PHARMACOKINETICS OF M1, M2, M3, AND M4 AFTER INTRAVENOUS ADMINISTRATION OF DA-125 OR ME2303 TO MICE AND RATS. NEW ADRIAMYCIN ANALOGUES CONTAINING FLUORINE. , 1996, 17, 373-420.		2
92	Gender differences in the hepatic elimination and pharmacokinetics of lobeglitazone in rats. Biopharmaceutics and Drug Disposition, 2015, 36, 410-415.	1.9	2
93	Nanoformulations of Carfilzomib for Improved Metabolic Stability and Anti ancer Efficacy. FASEB Journal, 2015, 29, 620.1.	0.5	2
94	A Simple Decision Tree Suited for Identification of Early Oral Drug Candidates With Likely Pharmacokinetic Nonlinearity by Intestinal CYP3A Saturation. Journal of Pharmaceutical Sciences, 2021, 110, 510-516.	3.3	0
95	CNS-penetrant LMP2 Inhibitors as Potential Therapies for Age-related Macular Degeneration. SSRN Electronic Journal, 0, , .	0.4	0
96	Development of Epoxyketoneâ€based Immunoproteasomeâ€selective Inhibitors with Enhanced Brain Distribution In Vivo. FASEB Journal, 2019, 33, 670.19.	0.5	0